Cząsteczka VCAM1 na ścianach naczyń krwionośnych łączy onkogenną sygnalizację KRAS z zapaleniem komórek immunologicznych i krwotokami w mózgowych naczyniakach tętniczo-żylnych

Preprint (medRxiv/bioRxiv)➕ 19.11.2026Preprint (medRxiv/bioRxiv)

Endothelial VCAM1 links oncogenic KRAS signaling to myeloid inflammation and hemorrhagic instability in brain arteriovenous malformations

W skrócie

[Preprint - wstępne wyniki] Naukowcy odkryli, że cząsteczka VCAM1 na wewnętrznej powierzchni naczyń krwionośnych w mózgu odgrywa kluczową rolę w rozwoju niebezpiecznych krwotoków u pacjentów z arteriovenous malformations (AVM) - nieprawidłowymi połączeniami między tętnicami a żyłami. Badania na zwierzętach i materiałach od pacjentów wykazały, że zablokowanie VCAM1 zmniejszyło zapalenie i krwotoki w mózgu. Wyniki sugerują, że VCAM1 może być nowym celem terapeutycznym do zapobiegania poważnym powikłaniom AVM.

Oryginalny abstract (angielski)

BACKGROUND: Hemorrhagic conversion is the most devastating complication of brain arteriovenous malformations (bAVMs). However, endothelial mechanisms promoting macrophages (Mφ) recruitment, microglia (MG) activation, and bAVM lesion instability remain unclear. We investigated vascular cell adhesion molecule-1 (VCAM1) as a mediator linking oncogenic endothelial signaling to myeloid cell responses and hemorrhagic progression in bAVMs. METHODS: We performed integrated transcriptomic analysis of human bAVM and epilepsy-control brain tissues, with validation in local bAVM specimens. Transcriptomic and proteomic analyses of bAVM lesions and intact brain tissues from mutant KRAS-induced bAVM mice were followed by histological validation. Using AAV-BR1-KRASG12V-injected Cx3cr1-gfp;Ccr2-rfp mice, we performed intravital imaging to assess Mφ/MG responses to VCAM1 neutralization. Hemorrhage and myeloid cell responses were also evaluated following endothelial-specific VCAM1 deletion. Plasma soluble VCAM1 (sVCAM1) was measured in patients with unruptured and ruptured bAVMs and unruptured aneurysm controls. Effects of sVCAM1 on MG activation were examined in vitro. RESULTS: Integrated human endothelial bulk and single-cell RNA-sequencing and tissue validation identified VCAM1 upregulation in bAVMs, including unruptured lesions. Plasma analyses showed increased sVCAM1 in unruptured and ruptured bAVM patients compared with unruptured aneurysm controls. In mutant KRAS-induced bAVM mice, transcriptomic and proteomic analyses demonstrated increased VCAM1 expression, with endothelial localization confirmed histologically. In vitro, mutant KRAS increased sVCAM1 production, while recombinant sVCAM1 stimulated inflammatory mediator expression in MG. Both MG and Mφ expressed VLA-4, a major VCAM1 receptor. Intravital imaging showed that VCAM1 neutralization reduced Mφ accumulation and MG activation, while early VCAM1 neutralization reduced hemorrhagic burden. Consistently, endothelial-specific VCAM1 deletion reduced Mφ accumulation, MG activation, and hemorrhage volume in bAVM mice and improved behavioral performance. CONCLUSIONS: These findings identify endothelial VCAM1 as an upstream mediator linking mutant KRAS signaling to myeloid cell responses and hemorrhagic progression in bAVMs. This study establishes endothelial VCAM1 as a potential therapeutic target for attenuating hemorrhagic progression.

Metadane publikacji

Journal
Preprint (medRxiv/bioRxiv)
Data publikacji
18.11.2026
DOI
10.64898/2026.11.15.766869
Europe PMC ID
PPR1371204
Autorzy
Park ES, Park J, Park H, Myint O, Kang SW, Chen X, Zhao Z, Choi JM, Jung SY, Huang S
Źródło
Preprint (medRxiv/bioRxiv)